MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/ehf2.15414

Медицинская библиотека · ESC heart failure · 2025

A new staging system for hereditary transthyretin amyloidosis in the era of specific amyloidosis therapies.

Neculae Gabriela, Zaroui Amira, Adam Robert, Kharoubi Mounira, Funalot Benoit, Coriu Daniel, Jurcut Ruxandra, Damy Thibaud

СтатьяМногоцентровое исследованиеПеревод пока не подготовлен

Аннотация

OBJECTIVES

Currently, there are two prognosis staging systems validated for transthyretin amyloidosis (ATTR). We sought to develop a new staging system dedicated to hereditary transthyretin amyloidosis (ATTRv) patients on specific treatments.

METHODS AND

RESULTS

A total of 258 patients diagnosed with ATTRv from two cardiac amyloidosis reference centres in France and Romania were stratified into three disease stages based on NT-proBNP, estimated glomerular filtration rate (eGFR) and global longitudinal strain (GLS). A staging system was created using the following criteria: GLS ≥ -11%, NT-proBNP ≥ 2000 ng/L and eGFR ≤ 65 mL/min. Stage I was defined as the presence of none of the criteria. Stage III was defined as GLS ≥ -11% and either one or both NT-proBNP and eGFR criteria, while the remaining patients were defined as Stage II. Stage I patients had a 98.5% (95% CI 94.8-100) 5-year survival rate, Stage II patients 75.1% (95% CI 64.8-87.1) and Stage III patients a 29.4% (95% CI 18.6-46.5) 5-year survival rate (Stage I vs. Stage II, P = 0.001; Stage II vs. Stage III, P < 0.001). After age is adjusted for, compared to Stage I, the hazard ratio (HR) for death was 9.9 (95% CI 1.28-76.27, P = 0.02) for Stage II and 39.75 (95% CI 5.28-299.54, P < 0.001) for Stage III patients. HRs and statistical significance were maintained across different ATTR genotypes. The staging system was validated in a cohort of 138 patients.

CONCLUSIONS

We propose a novel staging system for ATTRv patients on specific treatment, based on two biological markers and one echocardiographic parameter, common in clinical practice.

Для цитирования: Neculae Gabriela, Zaroui Amira, Adam Robert, Kharoubi Mounira, Funalot Benoit, Coriu Daniel, Jurcut Ruxandra, Damy Thibaud. A new staging system for hereditary transthyretin amyloidosis in the era of specific amyloidosis therapies.. ESC heart failure. 2025. DOI: 10.1002/ehf2.15414.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.